6.93
-0.36 (-4.94%)
| Previous Close | 7.29 |
| Open | 7.15 |
| Volume | 8,153,344 |
| Avg. Volume (3M) | 18,068,984 |
| Market Cap | 7,258,162,688 |
| Price / Sales | 51.35 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Operating Margin (TTM) | -390.08% |
| Diluted EPS (TTM) | -0.570 |
| Quarterly Revenue Growth (YOY) | 41,192.50% |
| Current Ratio (MRQ) | 2.22 |
| Operating Cash Flow (TTM) | -370.16 M |
| Levered Free Cash Flow (TTM) | -251.77 M |
| Return on Assets (TTM) | -55.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ImmunityBio, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.38 |
|
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 74.11% |
| % Held by Institutions | 9.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Woodline Partners Lp | 31 Mar 2026 | 3,447,346 |
| Voloridge Investment Management, Llc | 31 Mar 2026 | 2,927,552 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 23.00 (D. Boral Capital, 231.89%) | Buy |
| Median | 18.00 (159.74%) | |
| Low | 13.00 (BTIG, 87.59%) | Buy |
| Average | 18.00 (159.74%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.14 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 12 Mar 2026 | 13.00 (87.59%) | Buy | 7.82 |
| D. Boral Capital | 09 Mar 2026 | 23.00 (231.89%) | Buy | 8.45 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |